HLA-B*5701 screening prior to abacavir prescription: Clinical and laboratory aspects

References

• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491.
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857–865.
   PubMed Web of Science ®Google Scholar
• Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126: 608–614.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134–4139.
   PubMed Web of Science ®Google Scholar
• Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005; 65: 285–302.
   PubMed Web of Science ®Google Scholar
• Faletto MB, Miller WH, Garvey EP, St. Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41: 1099–1107.
   PubMed Web of Science ®Google Scholar
• Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 2002; 142: 135–154.
   PubMed Web of Science ®Google Scholar
• Lockley DL, Howes D, Williams FM. Cutaneous metabolism of glycol ethers. Arch Toxicol 2005; 79: 160–168.
   PubMed Web of Science ®Google Scholar
• Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822–832.
   PubMed Web of Science ®Google Scholar
• Martin AM, Almeida CA, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21: 1233–1244.
   Google Scholar
• Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603–1614.
   PubMed Web of Science ®Google Scholar
• Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, Moore MA, Brothers CH, Scott TR. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38: 2171–2172.
   PubMed Web of Science ®Google Scholar
• Peyriere H, Guillemin V, Lotthe A, Baillat V, Fabre J, Favier C, Atoui N, Hansel S, Hillaire-Buys D, Reynes J. Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother 2003; 37: 1392–1397.
   PubMed Web of Science ®Google Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615–1627.
   PubMed Web of Science ®Google Scholar
• Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7: 324–330.
   PubMed Web of Science ®Google Scholar
• Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys D, Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422–428.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR; CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038–1046.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3d, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Three- vs. four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769–781.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir- lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285: 1155–1163.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979–981.
   PubMed Web of Science ®Google Scholar
• Peyrieère H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother 2001; 35: 1291–1292.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727–732.
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121–1122.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180–4185.
   PubMed Web of Science ®Google Scholar
• Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD, CNA30027 Study Team/CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203–211.
   PubMed Web of Science ®Google Scholar
• Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99–102.
   PubMed Web of Science ®Google Scholar
• Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. In: Program and Abstracts of the Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, USA, 2006. Abstract 14.270. Antivir Ther 2006; 11(Suppl3): S1–S192.
   Google Scholar
• Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45: 1–3.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, García-Gascó P, Blanco F, González-Pardo G, Castellares C, Moreno V, Jiménez-Nácher I, González-Lahoz J, Soriano V. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses 2007; 23: 1374–1376.
   PubMed Web of Science ®Google Scholar
• Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008; 22: 1673–1675.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827–843.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M, for the Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen–b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46: 1111–1118.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555–570.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp 1–146. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 20, 2009.
   Google Scholar
• Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B and C alleles in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62: 1009–1030.
   PubMed Web of Science ®Google Scholar
• Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8: 36–41.
   PubMedGoogle Scholar
• Hammond E, Almeida C-A, Mamotte C, Nolan D, Phillips E, Schollaardt TA, Gill MJ, Angel JB, Neurath D, Li J, Giulivi T, McIntyre C, Koultchitski G, Wong B, Reis M, Rachlis A, Cole DE, Chew CB, Neifer S, Lalonde R, Roger M, Jeanneau A, Mallal S. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther 2007; 12: 1027–1032
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence based typing. Tissue Antigens 2005; 65: 571–574.
   PubMed Web of Science ®Google Scholar
• Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens 2007; 70: 58–61.
   PubMedGoogle Scholar
• Sayer DC, Cassell HS, Christiansen FT. HLA-B*27 typing by sequence-specific amplification without DNA extraction. Mol Pathol 1999; 52: 300–301.
   PubMedGoogle Scholar
• Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; 16: 353–357.
   PubMed Web of Science ®Google Scholar
• de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, Ke X, Monsuur AJ, Whittaker P, Delgado M, Morrison J, Richardson A, Walsh EC, Gao X, Galver L, Hart J, Hafler DA, Pericak-Vance M, Todd JA, Daly MJ, Trowsdale J, Wijmenga C, Vyse TJ, Beck S, Murray SS, Carrington M, Gregory S, Deloukas P, Rioux JD. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006; 38: 1166–1172.
   PubMed Web of Science ®Google Scholar
• Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944–947.
   PubMed Web of Science ®Google Scholar
• Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C, Thurnheer C, Günthard HF, Goldstein DB, Furrer H, Telenti A, and the Swiss HIV Cohort Study. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008; 198: 864–867.
   PubMed Web of Science ®Google Scholar
• Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44: 1503–1508.
   PubMed Web of Science ®Google Scholar
• Waters LJ, Mackie NE, Pozniak A, Winston A. Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701. Clin Infect Dis 2007; 45:1243–1244.
   PubMed Web of Science ®Google Scholar
• Gerber BO, Pichler WJ. Cellular mechanisms of T-cell-mediated drug hypersensitivity. Curr Opin Immunol 2004; 16: 732–737.
   PubMed Web of Science ®Google Scholar
• Teoh CY, Davies KJ. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the ‘PrOxI’ hypothesis. Arch Biochem Biophys 2004;423:88–96.
   PubMed Web of Science ®Google Scholar
• Almeida CA, Martin AM, Nolan D, Lucas A, Cameron PU, James I, Phillips E, Mallal S. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008; 13: 281–288.
   PubMed Web of Science ®Google Scholar
• Telenti A, Aubert V, Spertini F. Individualising HIV treatment—pharmacogenetics and immunogenetics. Lancet 2002; 359: 722–723.
   PubMed Web of Science ®Google Scholar
• Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J. Components of the ligand for a Ni++ reactive human T cell clone. J Exp Med 2003; 197: 567–574.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262: 242–244.
   PubMed Web of Science ®Google Scholar
• Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155, 452–472.
   Web of Science ®Google Scholar
• Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP. Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44: 1324–1332.
   PubMed Web of Science ®Google Scholar
• Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1617–1638.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–305.
   PubMed Web of Science ®Google Scholar
• Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR Study Group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99–107.
   PubMed Web of Science ®Google Scholar
• Australasian and South East Asian Tissue Typing Association (ASEATTA) Quality Assurance Programs website. Available at http://www.aseatta.org.au/qap.htm. Accessed April 20, 2009.
   Google Scholar